Vaxxas today announced that it has initiated a multi-center Phase I clinical trial of a vaccine against pre-pandemic avian ...

"Each flu virus, which we call influenza, has a hemagglutinin protein that initiates an infection when it attaches to cells .

Cell culture-based or recombinant influenza vaccines will contain: HA derived from an influenza A/Wisconsin/67/2022 (H1N1)pdm09-like virus, an influenza A/Massachusetts/18/2022 (H3N2)-like virus ...

The Centers for Disease Control and Prevention recommend that everyone 6 months of age and older get the flu and COVID-19 ... NovaVax, which is a protein-based vaccine, has not yet been approved ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer ... than shots made using traditional cell culture or recombinant techniques.

Moderna, Inc.'s combination flu ... based on recent feedback and discussions with country health officials. Second, in the U.S. we are seeing increased competitive pressures for our respiratory ...

Nov. 25, 2022 — An experimental mRNA-based vaccine against all 20 known subtypes of influenza virus provided broad protection from otherwise lethal flu strains in initial tests, and thus might ...

based on mRNA technology, might do a better job at shielding recipients from harm. Advertisement The findings were published Wednesday in the journal Cell. "With the mRNA vaccine, we're able to ...

A recent study published in the Journal of Virology discusses a recent vaccine candidate that has the potential to neutralize both existing and emerging flu viruses effectively. According to the ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...